8-K: Bluejay Diagnostics: All Prefunded Warrants Exercised

Bluejay Diagnostics announced that all prefunded warrants from its October 2025 private placement have been fully exercised, resulting in approximately 972,000 common shares outstanding.

Summary

• All prefunded warrants issued in the October 2025 private placement have been fully exercised as of February 19, 2026.
• The company no longer has any prefunded warrants of any class or tranche outstanding.
• Bluejay Diagnostics now has approximately 972,000 shares of common stock outstanding.
• An additional 1.5 million shares are subject to cash exercisable warrants with an exercise price of $7.00 or greater per share.
• Recent Schedule 13G filings by investors do not reflect the 1-for-4 reverse stock split that occurred on January 29, 2026, potentially overstating beneficial ownership on a post-split basis.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive update, as the full exercise of prefunded warrants strengthens the balance sheet and simplifies the capital structure, though the lack of FDA clearance for its core product remains a significant overhang.

Positives

• Full exercise of prefunded warrants indicates investor confidence and provides capital to the company.
• Elimination of all prefunded warrants simplifies the capital structure.

Negatives

• The warning about Schedule 13G filings not reflecting the reverse stock split could lead to investor confusion regarding actual beneficial ownership.
• The company's primary product, the Symphony System, still lacks regulatory clearance from the U.S. FDA, which is critical for commercialization.

Risks

• The company does not yet have regulatory clearance for its Symphony System and requires FDA authorization before it can be marketed as a diagnostic product in the United States.
• Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors, including market conditions and those discussed in previous SEC filings (Form 10-K for Dec 31, 2024, and Form 10-Q for Mar 31, 2025, June 30, 2025, and Sep 30, 2025).

Future Outlook

The company's future success is contingent on receiving regulatory authorization from the U.S. Food and Drug Administration for its Symphony System, which is currently not cleared for marketing as a diagnostic product.

Management Comments

• "Bluejay Diagnostics today announced that as of February 19, 2026, all of the prefunded warrants issued by the Company in its October 2025 private placement have been fully exercised, and the Company has no remaining prefunded warrants of any class or tranche outstanding."
• "The Company notes that several recent Schedule 13G filings made by investors do not reflect the 1-for-4 reverse stock split that occurred on January 29, 2026, and investors reading such filings should be aware that current beneficial ownership share amounts may therefore be significantly less than the number of shares reflected in such reports given that these reports show holdings and total shares outstanding on a pre-split basis, notwithstanding that such reports were filed after consummation of the 1-for-4 reverse stock split."

Industry Context

StockSavvy.ai notes that the medical diagnostics industry is highly regulated, with FDA clearance being a critical hurdle for product commercialization. Companies like Bluejay Diagnostics, focusing on rapid, near-patient testing for conditions like sepsis, operate in a competitive landscape with significant market potential if regulatory approvals are secured. The capital structure updates are typical for emerging growth companies seeking to optimize their financial position.

Comparison to Industry Standards

• The exercise of prefunded warrants is a standard mechanism for early investors to convert their instruments into common equity, often seen in biotech and medical device companies post-IPO or private placement.
• Reverse stock splits, such as the 1-for-4 split by Bluejay, are common for companies seeking to maintain compliance with exchange listing requirements or to make their stock more attractive to institutional investors, similar to actions taken by other small-cap biotechs like Aeterna Zentaris (AEZS) or Sorrento Therapeutics (SRNEQ) in the past.
• The challenge of obtaining FDA clearance for diagnostic systems, like Bluejay's Symphony System, is a universal hurdle in the medical diagnostics sector, comparable to the regulatory pathways navigated by companies such as QuidelOrtho (QDEL) or Bio-Rad Laboratories (BIO) for their diagnostic platforms.

Stakeholder Impact

• Shareholders: The increase in common shares outstanding (to 972,000) and the potential for further dilution from 1.5 million cash exercisable warrants could impact per-share metrics. The clarification on the reverse stock split helps prevent confusion regarding beneficial ownership.
• Investors: Provides clarity on the company's current capital structure and outstanding warrants.

Next Steps

• Continue efforts to obtain regulatory authorization from the U.S. Food and Drug Administration for the Symphony System.
• Further development and potential marketing of the IL-6 Test for sepsis upon regulatory clearance.

Key Dates

Recommendation

While the full exercise of prefunded warrants is a positive step for Bluejay Diagnostics, providing capital and simplifying its structure, the company's core product, the Symphony System, still lacks crucial FDA regulatory clearance. This significant hurdle means the company's commercial viability and future revenue streams remain uncertain. The potential for further dilution from outstanding cash exercisable warrants also warrants caution. Investors should hold, awaiting further progress on regulatory approvals and clearer pathways to commercialization before considering a stronger position.

Keywords

Bluejay Diagnostics, BJDX, Warrants, Stock Split, Capitalization, Sepsis, Medical Diagnostics, FDA Clearance, Symphony System, IL-6 Test